A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Roche

Status: Completed

Conditions: Locally Advanced Breast Cancer; Metastatic Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT02595762

ML28801

Details and patient eligibility

About

This disease registry is a prospective, multicenter non-interventional study designed to observe anti-cancer treatment regimens and clinical outcomes in participants with HER2-positive unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (MBC).

Enrollment: 110 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of HER2-positive unresectable LABC or MBC within 6 months prior to enrollment

Exclusion criteria

• None specified

Trial design

110 participants in 1 patient group

Participants With HER2-Positive Breast Cancer

Description:

Enrolled participants will receive treatment and clinical assessments for their HER2-positive unresectable LABC/MBC as determined by their treating physician, according to the standard of care and routine clinical practice at each site. Participants will be followed until death, withdrawal of consent or study termination, whichever occurs first. Study protocol does not specify any particular drug or treatment regimen.